Finance

Lists
Q2 2027 earnings • in 4 days
See details
500087:BOM
Cipla Ltd
₹1,321.20
-0.65%
(-8.70) 1D
Oct 23, 1:17:47 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500087...
Open
₹1,336.00
High
₹1,336.70
Low
₹1,313.55
Mkt. cap
1.07T
Avg. vol.
38.26K
Volume
25.60K
Dividend
0.98%
Quarterly dividend
₹3.25
Ex-dividend date
Jun 5, 2026
P/E ratio
31.68
52-wk high
₹1,672.20
52-wk low
₹1,165.55
EPS
₹41.70
Shares outstanding
805.67M
No. of employees
31K
Open
₹1,336.00
High
₹1,336.70
Low
₹1,313.55
Mkt. cap
1.07T
Avg. vol.
38.26K
Volume
25.60K
Dividend
0.98%
Quarterly dividend
₹3.25
Ex-dividend date
Jun 5, 2026
P/E ratio
31.68
52-wk high
₹1,672.20
52-wk low
₹1,165.55
EPS
₹41.70
Shares outstanding
805.67M
No. of employees
31K
News stories
From web sources and news partners
Profile
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India. Wikipedia
About Cipla Ltd
CEOUmang Vohra
Employees31.4K
Founded1935
HeadquartersMumbai, Maharashtra, India
SectorPharmaceutical industry
Websitecipla.com
Next call in 4 days
Tue, Oct 27, 12:30 PM
Fiscal period
Q2 2027
- / ₹11.83
Revenue / Est. (INR)
- / 76.34B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
74.47B
69.63B
65.80B
70.77B
Cost of goods sold
24.98B
26.32B
25.10B
26.67B
Cost of revenue
24.98B
26.32B
25.10B
26.67B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.15B
13.25B
28.23B
14.97B
Operating expense
33.52B
33.54B
33.30B
35.22B
Total operating expenses
58.50B
59.86B
58.39B
61.89B
Operating income
15.98B
9.77B
7.41B
8.88B
Other non operating income
2.69B
2.06B
-5.35B
2.11B
EBT including unusual items
18.54B
8.93B
6.99B
10.80B
EBT excluding unusual items
18.54B
11.69B
4.51B
10.80B
Income tax expense
5.00B
2.19B
1.57B
2.95B
Effective tax rate
27.00%
24.48%
22.44%
27.29%
Other operating expenses
17.40B
17.51B
2.51B
17.20B
Net income
13.51B
6.76B
5.55B
7.89B
Net profit margin
18.14%
9.71%
8.43%
11.15%
Earnings per share
16.72
10.94
6.86
9.76
Interest and investment income
-
-
2.07B
-
Interest expense
-131.80M
-140.30M
-69.70M
-170.30M
Net interest expenses
-131.80M
-140.30M
2.00B
-170.30M
Depreciation and amortization charges
2.97B
2.78B
2.56B
3.04B
EBITDA
18.73B
12.00B
9.82B
11.29B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps